This article was originally published in The Tan Sheet
Sales of its worldwide self- medication business increased 6.4% in the first half of 1994 to reach $339.2 mil. from $319.9 mil. in the first six months of 1993, Ciba reported Aug. 31. Ciba said that the self-medication division "performed particularly well in the U.S. due to the Efidac/24 cold treatment and acquired Fisons products." Ciba, which had looked at acquiring Sterling's OTC business prior to SmithKline's purchase of Sterling, is understood to be considering expanding its U.S. OTC activities
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC